US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Innate Pharma

2.16

0.0000

Volume:50.00

Turnover:82.88

Market Cap:198.60M

PE:-3.41

High:2.16

Open:2.16

Low:2.16

Close:2.16

52wk High:2.90

52wk Low:1.31

Shares:92.16M

Float Shares:34.42M

Volume Ratio:0.09

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6319

EPS(LYR):-0.6319

ROE:-271.37%

ROA:-25.92%

PB:32.67

PE(LYR):-3.41

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Innate Pharma Releases Share and Voting Rights Update as of November 27, 2025

Innate Pharma’s Q3 2025 Update: FDA Clears Phase 3 Trial for Lacutamab

ADRs Advance; Innate Pharma S.A. Climbs 30%

Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IPHYF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IPHYF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPHYF\",,,,,undefined,":{"symbol":"IPHYF","market":"US","secType":"STK","nameCN":"Innate Pharma","latestPrice":2.155,"timestamp":1770396217368,"preClose":2.155,"halted":0,"volume":50,"delay":15,"changeRate":0,"floatShares":34422236,"shares":92157798,"eps":-0.63191,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 11:43:37 EST Delay","open":2.155,"high":2.155,"low":2.155,"amount":82.875,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.63191,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":2.155,"volumeRatio":0.088968},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPHYF\",,,,,undefined,":{"symbol":"IPHYF","floatShares":34422236,"roa":"-25.92%","roe":"-271.37%","lyrEps":-0.63191,"volumeRatio":0.088968,"shares":92157798,"dividePrice":0,"high":2.155,"amplitude":0,"preClose":2.155,"low":2.155,"week52Low":1.31,"pbRate":"32.67","psRate":"13.30","week52High":2.9,"institutionHeld":0,"latestPrice":2.155,"eps":-0.63191,"divideRate":0,"volume":50,"delay":15,"ttmEps":-0.63191,"open":2.155,"prevYearClose":2.155,"prevWeekClose":2.155,"prevMonthClose":2.155,"prevQuarterClose":2.155},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPHYF\",params:#limit:5,,,undefined,":[{"date":"2024-05-14","symbol":"IPHYF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"Pre-Market","dateTimestamp":1715659200000,"actualEps":null},{"market":"US","date":"2022-11-07","symbol":"IPHYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1667797200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-09-15","symbol":"IPHYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1663214400000,"reportTimeType":"","actualEps":null},{"date":"2022-03-24","symbol":"IPHYF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1648108800000,"name":null,"time":"Pre-Market","dateTimestamp":1648094400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPHYF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPHYF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1761714000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPHYF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586733998","title":"Innate Pharma Releases Share and Voting Rights Update as of November 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2586733998","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586733998?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:27","pubTimestamp":1764340076,"startTime":"0","endTime":"0","summary":"Innate Pharma SA ( ($FR:IPH) ) has provided an update. On November 28, 2025, Innate Pharma S.A. released its total number of shares and voting righ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharma-releases-share-and-voting-rights-update-as-of-november-27-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharma-releases-share-and-voting-rights-update-as-of-november-27-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","BK4139"],"gpt_icon":0},{"id":"2583561298","title":"Innate Pharma’s Q3 2025 Update: FDA Clears Phase 3 Trial for Lacutamab","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561298","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561298?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:38","pubTimestamp":1763033924,"startTime":"0","endTime":"0","summary":"Innate Pharma SA ( ($FR:IPH) ) has shared an update. Innate Pharma S.A. reported its third-quarter 2025 business update and financial results, high...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-q3-2025-update-fda-clears-phase-3-trial-for-lacutamab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-q3-2025-update-fda-clears-phase-3-trial-for-lacutamab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","BK4139"],"gpt_icon":0},{"id":"2582383896","title":"ADRs Advance; Innate Pharma S.A. Climbs 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582383896","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582383896?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:30","pubTimestamp":1762810200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Monday, as the S&P/BNY Mellon index of American depositary receipts increased 1.6% to 231.45.The European index increased 1.4% to 202.63. The Asian index added 1.8% to 311.52. The Latin American index gained 0.8% to 235.78, while the emerging-markets index rose 2.1% to 525.67.France's Innate Pharma S.A. was the biggest leader during the session, rocketing 30% to $2.30, and Singapore-based Trident Digital Tech Holdings Ltd. jumped 18% to 70 cents. XPeng Inc., which is based in China, rounded out the top three leaders on Monday, with shares jumping 16% to $26.04.Zepp Health Corp., based in China, posted the largest decline, plunging 18% to $22.40, followed by shares of United Kingdom's Barinthus Biotherapeutics PLC, which tumbled 18% to 88 cents. Shares of United Kingdom-based Wing Yip Food Holdings Group Ltd. plunged 10% to 91 cents.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IPHYF"],"gpt_icon":0},{"id":"2582443821","title":"Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2582443821","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582443821?lang=en_us&edition=fundamental","pubTime":"2025-11-10 17:45","pubTimestamp":1762767958,"startTime":"0","endTime":"0","summary":"Innate Pharma  said Monday that the US Food and Drug Administration completed a review of its confirmatory phase 3 protocol for lacutamab as a possible treatment for cutaneous T-cell lymphomas, clearing the trial to move forward.The phase 3 trial is designed to show the efficacy of lacutamab in patients with Sezary syndrome and Mycosis fungoides who have failed at least one prior line of therapy, the company said.The trial, set to begin in H1 2026, will include separate cohorts for patients with Sezary syndrome and mycosis fungoides, with progression-free survival as the primary endpoint, the company said.The company said the FDA provided \"encouraging initial feedback\" on its proposed regulatory pathway, which could potentially include accelerated approval for the Sezary syndrome indication once the Phase 3 trial is underway.Sezary syndrome is a rare cancer impacting the skin and blood, while mycosis fungoides is the most common type of skin cancer.Shares of the company were up 16% in ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPHYF","IPHA","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IPHYF\",params:#limit:6,delay:false,,,undefined,":[]}}